Search Orphan Drug Designations and Approvals
-
| Generic Name: | levodopa and carbidopa | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Duopa | ||||||||||||||||
| Date Designated: | 01/18/2000 | ||||||||||||||||
| Orphan Designation: | Treatment of late stage Parkinson's disease | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
AbbVie, Inc. 1 N. Waukegan Road Building AP30-1 North Chicago, Illinois 60064 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | levodopa and carbidopa |
|---|---|---|
| Trade Name: | Duopa | |
| Marketing Approval Date: | 01/09/2015 | |
| Approved Labeled Indication: | Treatment of motor flucuations in patients with advanced Parkinson's disease | |
| Exclusivity End Date: | 01/09/2022 | |
| Exclusivity Protected Indication* : | Treatment of motor flucuations in patients with advanced Parkinson's disease | |
-
